EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )

Jaime P Almandoz iD, Beverly G Tchang iD, Kelley Myers iD, Andrea Traina iD, Jigish Bhavsar iD, Victoria Divino iD, Cannon Kent iD, Sara Tadesse Bell iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11485-11495

DOI: 10.1111/dom.71318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.09.2026. Verfasst von Jaime P Almandoz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Obesity, Overweight, Anti-Obesity Agents, Patient Preference. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed‐choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random‐parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice.

Results

Among 800 participants (400 OM‐naïve/400 OM‐experienced, 400 injection‐naïve/400 injection‐experienced), the most important attributes were route of administration, average weight‐loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A—a hypothetical oral semaglutide‐like profile) over the alternative OM profile (Treatment B—a hypothetical orforglipron‐like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed‐choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM‐naïve participants were open to taking an oral OM.

Conclusions

Individuals with overweight or obesity prioritise weight‐loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityOverweightAnti-Obesity AgentsPatient PreferenceChoice BehaviorHumansUnited StatesFemaleMaleAdultMiddle AgedSemaglutideWeight LossCardiovascular DiseasesSurveys and QuestionnairesGlucagon-Like Peptides

Stichwörter der Autor:innen

GLP‐1 analogueantiobesity drugcardiovascular diseaseobesity therapysemaglutideweight management

Substanzen

Anti-Obesity AgentsSemaglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Clinical Medicine, Weill Cornell Medicine, New York, New York, USA.
  • RTI Health Solutions, Durham, North Carolina, USA.
  • Novo Nordisk Inc, Plainsboro, New Jersey, USA.

ORCID-Profile: Jaime P Almandoz, Beverly G Tchang, Kelley Myers, Andrea Traina, Jigish Bhavsar, Victoria Divino, Cannon Kent, Sara Tadesse Bell

Förderung

  • Novo Nordisk

Zitieren

APA

Almandoz, J. P., Tchang, B. G., Myers, K., Traina, A., Bhavsar, J., Divino, V., Kent, C., & Bell, S. T. (2026). Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC ). Diabetes, Obesity and Metabolism, 28(12), 11485-11495. https://doi.org/10.1111/dom.71318

Vancouver

Almandoz JP, Tchang BG, Myers K, Traina A, Bhavsar J, Divino V, et al. Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC ). Diabetes, Obesity and Metabolism. 2026;28(12):11485-11495. doi:10.1111/dom.71318

BibTeX
@article{Almandoz2026,
  author = {Almandoz, Jaime P and Tchang, Beverly G and Myers, Kelley and Traina, Andrea and Bhavsar, Jigish and Divino, Victoria and Kent, Cannon and Bell, Sara Tadesse},
  title = {Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11485--11495},
  doi = {10.1111/dom.71318}
}
Kostenlos starten →